Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia

Nakamura, Hiroaki; Tsuji, Takehito; Hirata, Azumi; Yamamoto, Toshio

Affiliations

¹Department of Oral Morphology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan

Abstract and keywords

Osteoprotegerin (OPG), a soluble member of the tumor necrosis factor (TNF) receptor family, is an osteoclastogenesis inhibitory factor. We investigated the localization of OPG in rat tibia using a specific peptide antibody to clarify the role of OPG in bone remodeling. OPG reactivity was mainly seen on bone surfaces. In bone matrices, OPG was also localized on cartilage/bone interfaces and cement lines. However, labeling was scarcely detected in the region of contact between osteoclasts and stromal cells. Some osteoblasts and osteocytes showed weak labeling. Immunoreactivity was not seen in chondrocytes or osteoclasts. Immunoelectron microscopic observation revealed that OPG is localized on the bone surfaces under osteoclasts. These findings suggest that OPG derived from osteoblast lineage cells and/or serum may be concentrated on resorbed bone surfaces and subsequently on cement lines. OPG may play an important role in the prevention of excess bone resorption by inhibiting differentiation and activity of osteoclasts in bone remodeling.

Keywords: osteoprotegerin (OPG), osteoblasts, osteoclasts, cement line, bone remodeling, immunohistochemistry

Links

DOI: 10.1177/002215540205000708

PubMed: 12070273

WoS: 000176450700008

History

Received: 2001-10-16

Accepted: 2002-02-06

Cited Works (7)

Year	Entry
1998	Yasuda H, Shima N, Akagawa NN, Yamaguchi K, Kinosaki M, Mochizuki S-I, Omoyasu AT, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Igashio KH, Udagawa N, Tkahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. March 31, 1998;95(7):3597-3602.
1987	Schaffler MB, Burr DB, Frederickson RG. Morphology of the osteonal cement line in human bone. Anat Rec. March 1987;217(3):223-228.
1999	Nanci A. Content and distribution of noncollagenous matrix proteins in bone and cementum: relationship to speed of formation and collagen packing density. J Struct Biol. June 30, 1999;126(3):256-269.
1991	Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. December 1991;88(6):2095-2105.
1997	Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ; Amgen EST Program. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. April 18, 1997;89(2):309-319.
1995	McKee MD, Nanci A. Osteopontin and the bone remodeling sequence: colloidal-gold immunocytochemistry of an interfacial extracellular matrix protein. Annals NY Acad Sci. 1995;760(1):177-189.
1998	Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. April 17, 1998;93(2):165-176.